Doctor Sentenced to Suspended Prison Term for 200 Million Won Pharmaceutical Rebate for Prescriptions
Accepted Kickbacks for Choosing and Promoting Specific Pharmaceuticals
Court: "Increases Financial Burden on Patients"
A doctor who received approximately 200 million won in kickbacks for using and prescribing a specific company’s pharmaceuticals has been sentenced to a suspended prison term.
On April 7, Judge Lee Byungho of the 7th Criminal Division, Changwon District Court, announced that he had sentenced a doctor in his 60s, referred to as A, to one year in prison with two years of probation for violating the Medical Service Act, and ordered the forfeiture of 149,995,276 won.
The court also sentenced B, a freelance sales employee in his 60s at a pharmaceutical wholesale and retail company who was tried together for violating the Pharmaceutical Affairs Act, to six months in prison with one year of probation.
A, who runs an internal medicine clinic in Changwon, Gyeongsangnam-do, was indicted for accepting a total of 190,803,156 won in 1,044 separate instances—including meal payments—from February 2018 to May 2021 in exchange for choosing and promoting prescriptions of pharmaceuticals from B’s company.
B was also found to have acted as an office manager at the clinic, taking charge of administrative tasks such as recruiting staff, adjusting salaries, handling payments, and managing interior furnishings.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The court stated, “Pharmaceutical-related rebates undermine fair competition in the market and contribute to rising drug prices, thereby increasing the financial burden on patients, which makes this crime particularly serious.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.